Abstract:We read with great interest the American Association for the Study of Liver Diseases practice guideline1 showing the current central status of anticoagulation for portal vein thrombosis (PVT), although anticoagulation should never be stereotyped for all patients with PVT. It is very important for clinicians to distinguish between noncirrhotic and cirrhotic PVT because of its association with therapeutic strategy selection. Nonmalignant and noncirrhotic PVT is mainly caused by inherited and acquired prothrombotic disorders, except for some local factors, so the treatment should be focused on correction of these disorders and not on the creation of a hepatic parenchymal shunt and thrombectomy, which may be just a temporary rescue. According to our data for the period of December 2001 to September 2008, the outcome of noncirrhotic PVT by transjugular intrahepatic portosystemic shunt (TIPS) was unsatisfactory with respect to the technical success rate (9/23) and follow-up in patients with successful recanalization. In contrast, the outcome by anticoagulation therapy was inspiring, as many recent reports have shown.2, 3 The primary cause of cirrhotic PVT is portal flow reduction and its secondary hemostasis, even if other factors play a role, such as the decline of coagulation inhibitors synthesized by the liver and inherited coagulation abnormalities. Variceal rebleeding is one of the most common clinical presentations in patients with decompensated cirrhosis and PVT, at least in our aforementioned data (52/61). Therefore, the goal of treatment in theory is to deal with the portal hypertension and smooth portal vein. Benefits lie not only in a successful recanalization rate (43/61) but also in postoperative follow-up in our experience (Table 1). It seems that TIPS with thrombectomy should be adopted more widely than anticoagulation therapy (Fig. 1), which is still challenged by the unresolved issue4 of whether to aggravate the risk of bleeding or not, especially for patients with thrombocytopenia and large varices. Comparison of TIPS and anticoagulation. The cube represents a patient with cirrhosis and portal vein thrombosis in whom variceal rebleeding is a major presentation. Abbreviation: TIPS, transjugular intrahepatic portosystemic shunt. Definite primary thrombosis of the hepatic vessels was diagnosed. For example, Budd-Chiari syndrome had been recognized and treated a few years before the diagnosis of cirrhosis and PVT. Other local factors clearly existed, such as pancreatitis or splenectomy. Cirrhosis was in a compensated condition. In reverse, PVT with well-compensated cirrhosis should not be excluded from noncirrhotic PVT. The effect can be better only if we aim at the major etiology more accurately and choose a corresponding treatment. It is time to establish the feasibility and safety of TIPS for cirrhotic PVT and thereby design prospective studies, although we have to acknowledge the technical difficulty of TIPS with thrombectomy for PVT: only 28 cases have been studied retrospectively in the largest series5 since the first report.6 Xingshun Qi*, Guohong Han*, Daiming Fan*, * Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi'an, China.

Transjugular Intrahepatic Portosystemic Shunt Creation for Cirrhotic Portal Hypertension is Well Tolerated among Patients with Portal Vein Thrombosis.

Comparison of Transjugular Intrahepatic Portosystemic Shunt in the Treatment of Cirrhosis With or Without Portal Vein Thrombosis: A Retrospective Study

Association of Nonmalignant Portal Vein Thrombosis and Outcomes after Transjugular Intrahepatic Portosystemic Shunt in Patients with Cirrhosis

Systematic review and meta-analysis of trans-jugular intrahepatic portosystemic shunt for cirrhotic patients with portal vein thrombosis

Transjugular Intrahepatic Portosystemic Shunt for Portal Vein Thrombosis with Symptomatic Portal Hypertension in Liver Cirrhosis

P- 63 UTILITY OF TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT IN TREATING COMPLICATIONS OF PORTAL HYPERTENSION: EXPERIENCE IN UNIT OF LIVER TRANSPLANTATION IN URUGUAY

Transjugular Intrahepatic Portosystemic Shunt for Portal Cavernoma with Symptomatic Portal Hypertension in Non-Cirrhotic Patients.

Long-term Clinical Outcomes in Patients with Viral Hepatitis Related Liver Cirrhosis after Transjugular Intrahepatic Portosystemic Shunt Treatment

Transjugular Intrahepatic Portosystemic Shunt May Be Superior to Conservative Therapy for Variceal Rebleeding in Cirrhotic Patients with Non-Tumoral Portal Vein Thrombosis: a Hypothesis.

Transjugular intrahepatic portosystemic shunt creation for portal hypertension in patients with hepatocellular carcinoma: A systematic review

Use of concomitant variceal embolization and prophylactic antiplatelet/anticoagulative in transjugular intrahepatic portosystemic shunting: A retrospective study of 182 cirrhotic portal hypertension patients.

Is Post-TIPS Anticoagulation Therapy Necessary in Patients with Cirrhosis and Portal Vein Thrombosis? A Randomized Controlled Trial

Transjugular Intrahepatic Portosystemic Shunt for Symptomatic Portal Hypertension in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis.

Transjugular intrahepatic portosystemic shunt after liver transplantation: is patient selection the key to success?

[Transjugular Intrahepatic Portosystemic Shunt and Combination with Percutaneous Transhepatic or Transsplenic Approach for the Treatment of Portal Vein Thrombosis with or Without Cavernomatous Transformation].

Shunting Branch of Portal Vein and Stent Position Predict Survival after Transjugular Intrahepatic Portosystemic Shunt

Covered transjugular intrahepatic portosystemic shunt improves survival for variceal bleeding in cirrhotic patients with hepatic venous pressure gradient >= 16 mmHg: A comparison study

The Preferable Treatment for Cirrhotic Portal Vein Thrombosis: Anticoagulation or Transjugular Intrahepatic Portosystemic Shunt?

Transjugular Intrahepatic Portosystemic Shunt for Palliative Treatment of Portal Hypertension Secondary to Portal Vein Tumor Thrombosis

Clinical Study on Transjugular Intrahepatic Portosystemic Shunt in Treatment of Portal Hypertension of Patients with Hepatocellular Carcinoma

Transjugular Intrahepatic Portosystemic Shunt Creation for the Prevention of Gastric Variceal Rebleeding in Patients with Hepatocellular Carcinoma: A Multicenter Retrospective Study